Long-Lasting Stable Expression of Human LL-37 Antimicrobial Peptide in Transgenic Barley Plants
Quality Score
4/10
Citations
14
Subjects
Non-Human
Study Design
Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.
Our Assessment
Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.
Findings in Context
These findings advance our understanding of LL-37, human cathelicidin in meaningful ways.
On the Limitations
Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.
The Takeaway
Bottom line: Early-stage evidence for LL-37, human cathelicidin. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.
Key Findings
The study reports the stable expression and inheritance of human LL-37 antimicrobial peptide in transgenic barley plants over six generations, including field cultivation. The produced LL-37 retained high antibacterial activity.
Limitations
The research is preclinical and conducted on plant models rather than human subjects or clinical settings. It does not provide direct evidence for the therapeutic efficacy of LL-37 derived from transgenic barley in humans.
Citation
M. Mirzaee, E. Holásková, A. Mičúchová et al.. (2021). Long-Lasting Stable Expression of Human LL-37 Antimicrobial Peptide in Transgenic Barley Plants. Antibiotics. https://doi.org/10.3390/antibiotics10080898
Related Papers
Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.
Yuan Yihao et al. · ACS biomaterials science & engineering · 2025
LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity.
Wei Xubiao et al. · Cell reports · 2022
This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.